Signal Genetics Announces Master Service Agreement With Major Biopharmaceutical Partner
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Signal Genetics (SGNL) Signs Second MSA with for MyPRS; Success Could Lead to Larger Phase 3s
September 23, 2015 2:40 PM EDTChardan Capital affirms its Buy rating and $2.75 price target on Signal Genetics (Nasdaq: SGNL) after the company announced the signing of a... More
Signal Genetics (SGNL) and Major Biopharma Partner Sign Master Service Agreement
September 23, 2015 7:03 AM EDTSignal Genetics (Nasdaq: SGNL) announced the signing of a Master Service Agreement (MSA) with a leading biopharmaceutical company. The first two projects under this MSA will deploy Signal's proprietary MyPRS® test to inform the clinical stage development program of a novel treatment including potential combination therapies with current drugs for patients with multiple... More
